title: Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas.
authors.affiliation: Department of Medical Oncology, Institut Curie, Paris; Association pour l'Enseignement et la Recherche des Internes en Oncologie (AERIO), Paris.
authors.forename: M J
authors.initials: MJ
authors.lastname: Rodrigues
authors.affiliation: Association pour l'Enseignement et la Recherche des Internes en Oncologie (AERIO), Paris; Department of Medical Oncology, Institut Gustave Roussy, Villejuif.
authors.forename: L
authors.initials: L
authors.lastname: Albiges-Sauvin
authors.affiliation: Association pour l'Enseignement et la Recherche des Internes en Oncologie (AERIO), Paris; Department of Medical Oncology, Institut Curie/Hôpital René Huguenin, Saint-Cloud, France.
authors.forename: J
authors.initials: J
authors.lastname: Wassermann
authors.affiliation: Department of Medical Oncology, Institut Curie, Paris. Electronic address: paul.cottu@curie.net.
authors.forename: P H
authors.initials: PH
authors.lastname: Cottu
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab